Clinical trials: leukemia
Chronic Lymphocytic Leukemia
A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia
The purpose of this study is to assess safety and effectiveness of extended bendamustine in the treatment of chronic lymphocytic leukemia (CLL).
- Trial name
- NCT01739491
- Testing
- No intervention
- Sponsor
- Janssen Pharmaceutica
Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered…
- Conditions
- Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease, Mast Cell Leukemia, Relapsed or Refractory Myeloid Malignancies
- Trial name
- NCT02561988
- Testing
- Avapritinib
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 86 people
- Sponsor
- Blueprint Medicines Corporation
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Effect of Food on Blood Levels of ASTX727
This study is designed to examine blood levels of ASTX727, a fixed-dose combination tablet containing the combination of cedazuridine (100 mg) and decitabine (35 mg), when given under fed versus fasted conditions to participants…
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT03813186
- Testing
- ASTX727 + Day 2 Food, ASTX727 + Day 4 Food
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated…
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT03833180
- Testing
- Zilovertamab vedotin
- Where
- 14 sites in United States
- Volunteers
- 91 people
- Sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cancer, Hematologic Malignancies
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
This study of AMG 900 will be conducted in two parts: dose escalation and dose expansion. The dose escalation part of the study is aimed at evaluating the safety, tolerability and PK (pharmacokinetics) of oral AMG 900 in subjects…
- Conditions
- Cancer, Hematologic Malignancies, Leukemia, Myeloid Leukemia
- Trial name
- NCT01380756
- Testing
- Arm 1- Dose Escalation, Arm 2- Dose Expansion
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Amgen
Lymphoma, Acute Lymphoblastic Leukemia
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma.
- Trial name
- NCT02369653
- Testing
- Apixaban, No systemic anticoagulant prophylaxis
- Where
- 96 sites in United States, Australia and 10 more
- Volunteers
- 512 people
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukemia
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia
Phase 3 study to evaluate the efficacy and safety of dociparstat sodium in adults with newly diagnosed untreated acute myeloid leukemia (AML) with adverse or intermediate genetic risk.
- Trial name
- AML (NCT04571645)
- Testing
- Dociparstat, Control
- Where
- 14 sites in United States
- Volunteers
- 9 people
- Sponsor
- Jazz Pharmaceuticals
CLL/SLL
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.
- Trial name
- NCT06319456
- Testing
- Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine
- Where
- 10 sites in China
- Volunteers
- 344 people
- Sponsor
- Ascentage Pharma Group Inc.
Acute Myeloid Leukemia
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
This trial seeked to extend the preliminary findings of efficacy by evaluating MBG453 in combination with hypomethylating agents (HMA) and also Bcl-2 inhibitor venetoclax.
- Trial name
- STIMULUS-AML1 (NCT04150029)
- Testing
- MBG453, Venetoclax, Azacitidine
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 90 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia
Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
To evaluate the efficacy of PEG-BCT-100 in patients with relapsed or refractory acute myeloid leukemia (AML) in terms of remission rate.
- Trial name
- NCT02899286
- Testing
- PEG-BCT-100
- Where
- Hong Kong
- Volunteers
- 25 people
- Sponsor
- Bio-Cancer Treatment International Limited
AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome)
Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)
AlloHeme is a blood-based monitoring test developed by the CareDx laboratory that utilizes NGS technology coupled with a proprietary algorithm to predict the likelihood of a relapse in post-allo-HCT AML/MDS patients.
- Conditions
- AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), CMML
- Trial name
- FORWARD (NCT07607327)
- Testing
- AlloHeme
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- CareDx
Secondary Acute Myeloid Leukemia (Secondary AML, sAML)
Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study
Amonafide is a DNA intercalating agent and inhibitor of topoisomerase II that has been extensively studied in patients with malignant solid tumors. Amonafide has also been studied in patients with AML.
- Trial name
- NCT00715637
- Testing
- Daunorubicin and Cytarabine, Amonafide and Cytarabine
- Where
- 158 sites in United States, Argentina and 21 more
- Volunteers
- 420 people
- Sponsor
- Antisoma Research
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to…
- Trial name
- NCT05424822
- Testing
- JNJ-80948543
- Where
- 29 sites in United States, Australia and 6 more
- Volunteers
- 167 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Myeloid Leukemia
Asciminib RMP Study
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.
- Trial name
- NCT05943522
- Testing
- Asciminib
- Where
- 17 sites in South Korea
- Volunteers
- 600 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia
Phase III B in Acute Lymphoblastic Leukemia
This is a single arm, open-label, multi-center, phase III B study to determine the safety and efficacy of CTL019 in pediatric/young adult patients with r/r B-cell Acute Lymphoblastic Leukemia (ALL).
- Trial name
- NCT03123939
- Testing
- CTL019
- Where
- 11 sites in Austria, Belgium and 7 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r…
- Conditions
- Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia
- Trial name
- NCT04030195
- Testing
- PBCAR20A, Fludarabine, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Precision BioSciences, Inc.
Leukemia, Leukemia, Lymphocytic, Chronic
A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding…
- Trial name
- NCT00076401
- Testing
- Motexafin gadolinium
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Pharmacyclics LLC.
AML, Adult, Myelodysplastic Syndromes
EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
This open-label Phase I study aims to define the recommended dose for further clinical development the NKR-2 treatment administered concurrently with AZA in treatment-naïve AML/MDS patients not candidates for intensive…
- Trial name
- EPITHINK (NCT03612739)
- Testing
- NKR-2 CAR-T Cells
- Sponsor
- Celyad Oncology SA
Acute Myeloid Leukemia
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
This study compared treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine.
- Trial name
- VALOR (NCT01191801)
- Testing
- vosaroxin + cytarabine
- Where
- 124 sites in United States, Australia and 13 more
- Volunteers
- 711 people
- Sponsor
- Sunesis Pharmaceuticals
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
The purpose of the Phase I portion of this study is to evaluate the safety of this combination of medications and to determine the appropriate dose of VNP40101M to be used in combination with infusional cytarabine (araC) in…
- Trial name
- NCT00655395
- Testing
- Laromustine (VNP40101M) and Ara-C
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Viron Therapeutics Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.